CSPC Pharmaceutical Group Embarks on New Horizons, Targeting the Next BD Milestone

2 week ago / Read about 0 minute

Author：小编

CSPC Pharmaceutical Group and Madrigal Pharmaceuticals have inked a groundbreaking deal, whereby Madrigal will secure the worldwide exclusive license to develop, manufacture, and market SYH2086, an orally administered GLP-1 small molecule agonist independently crafted by CSPC. This agreement involves an upfront payment of USD 120 million, with potential milestone payments reaching up to USD 1.955 billion, totaling a maximum consideration of USD 2.075 billion. Notably, CSPC Pharmaceutical Group retains the exclusive rights to develop and commercialize additional orally administered GLP-1 small molecule products within the Chinese market.

Previous page：NDRC: Expediting Price Law Revision to Foster Scie...

Next page：WeChat Pay Introduces 'Lost Item Reminder' Feature

Return to List

Hot Reading

2 day ago

OpenAI Seems Really Confused About Why People Use ChatGPT

2 day ago

Duolingo CEO says controversial AI memo was misunderstood

1 day ago

Nalini Priya Uppari Established AI DOC Co-pilot at Enterprise Innovation with AI for Governance and Compliance as Her Organization's Core Business Focus

2 day ago

Watch Figure 02 Humanoid Fold Laundry in New AI Demo